Daniel Adu-Ampratwum, PhD
Research Assistant Professor
Medicinal Chemistry and Pharmacognosy
adu-ampratwum.1@osu.edu
Professional Interests
Many organic small molecules serve as drug leads for drug discovery and drug development programs. Understanding the structure and mechanism of action of these small molecules is essential for drug lead optimization. Also having a reliable synthetic access to these organic small molecules is important to aid in SAR studies and lead optimization in the search for new drugs for various diseases. Dr. Adu-Ampratwum's area of interest includes exploring novel synthetic methods for the synthesis of small organic molecules as lead compounds for drug discovery. His current research area focuses on designing and synthesizing small molecules to study HIV and cancer biology and as potential therapeutics.
Education
- 2016 – 2021 - Postdoctoral Researcher in Medicinal Chemistry – The Ohio State University, Columbus OH
- 2010 – 2016 - PhD in Chemistry – The Ohio State University, Columbus OH
- 2008 – 2010 – MS in Chemistry – Indiana University of Pennsylvania, Indiana PA
- 2002-2006 - BS in Chemistry – Kwame Nkrumah University of Science & Technology, Kumasi, Ghana
Publications
- RLSynC: Offline–Online Reinforcement Learning for Synthon Completion, Journal of Chemical Information and Modeling. 2024 Sep | journal-article. doi: 10.1021/acs.jcim.4c00554.
- Tomatidine targets ATF4-dependent signaling and induces ferroptosis to limit pancreatic cancer progression, iScience. 2023 Aug | journal-article. doi: 10.1016/j.isci.2023.107408.
- Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir, mBio. 2022 Oct | journal-article. doi: 10.1128/mbio.01804-22.
- Identification and Optimization of a Novel HIV-1 Integrase Inhibitor, ACS Omega. 2022 Feb | journal-article. doi: 10.1021/acsomega.1c06378.
- Structural and mechanistic bases for a potent HIV-1 capsid inhibitor, Science. 2020 Oct | journal-article. doi: 10.1126/science.abb4808.
- HIV-1 integrase tetramers are the antiviral target of pyridine-based allosteric integrase inhibitors, eLife. 2019 May | journal-article. doi: 10.7554/eLife.46344.
- An Isoquinoline Scaffold as a Novel Class of Allosteric HIV-1 Integrase Inhibitors, ACS Medicinal Chemistry. 2019 Jan | journal-article. doi: 10.1021/acsmedchemlett.8b00633.
- Stereochemical Definition of the Natural Product (6R,10R,13R, 14R,16R,17R,19S,20S,21R,24S,25S,28S,30S,32R,33R,34R,36S,37S,39R)‐Azaspiracid‐3 by Total Synthesis and Comparative Analyses, Angewandte Chemie International Edition. 2018 Jan | journal-article. doi: 10.1002/anie.201711008.
- Stereochemical Definition of the Natural Product (6R,10R,13R, 14R,16R,17R,19S,20S,21R,24S,25S,28S,30S,32R,33R,34R,36S,37S,39R)‐Azaspiracid‐3 by Total Synthesis and Comparative Analyses, Angewandte Chemie. 2018 Jan | journal-article. doi: 10.1002/ange.201711008.
- Total Synthesis of (6R,10R,13R,14R,16R,17R,19S,20R,21R,24S, 25S,28S,30S,32R,33R,34R,36S,37S,39R)‐Azaspiracid‐3 Reveals Non‐Identity with the Natural Product, Angewandte Chemie. 2018 Jan | journal-article. doi: 10.1002/ange.201711006.
- Total Synthesis of (6R,10R,13R,14R,16R,17R,19S,20R,21R,24S, 25S,28S,30S,32R,33R,34R,36S,37S,39R)‐Azaspiracid‐3 Reveals Non‐Identity with the Natural Product, Angewandte Chemie International Edition. 2018 Jan | journal-article. doi: 10.1002/anie.201711006.
- Synthesis of the C22–C40 Domain of the Azaspiracids, Organic Letters. 2016 Apr | journal-article. doi: 10.1021/acs.orglett.6b00557.